Lyell Immunopharma
Focus: Lyell Immunopharma is a clinical-stage biotech focused on curative cell-based immunotherapies for oncology and immunology indications. The company operates from South San Francisco with a lean, R&D-intensive structure.
Profile data last refreshed 5h ago · AI intelligence enriched 1w ago
Open Jobs
10-1 this month
Stable — net -1 jobs in 30d
5 added, 6 removed. Backfill posture.
Should You Work at Lyell Immunopharma?
AI assessmentLyell offers early-stage cell therapy exposure and near-term Phase 3 upside, but high execution risk and funding dependence make this suitable only for career stage tolerant of pre-commercial volatility.
Why Work Here
- Leading-edge cell therapy platform with rondecabtagene autoleucel in Phase 3 for large B-cell lymphoma—a near-term binary catalyst
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
A Biomarker Screening Protocol for Participants With Solid Tumors
Triple Negative Breast CancerClinical Trials (1)
NCT05891197A Biomarker Screening Protocol for Participants With Solid Tumors
N/AHelp build intelligence for Lyell Immunopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.